Buchumschlag

Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events

Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival. Although generally well tolerated, a minority of patients discontinue therapy due to gastr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Costabel, Ulrich (VerfasserIn) , Bendstrup, Elisabeth (VerfasserIn) , Cottin, Vincent (VerfasserIn) , Dewint, Pieter (VerfasserIn) , Egan, Jim J. J. (VerfasserIn) , Ferguson, James (VerfasserIn) , Groves, Richard (VerfasserIn) , Hellström, Per M. (VerfasserIn) , Kreuter, Michael (VerfasserIn) , Maher, Toby M. (VerfasserIn) , Molina-Molina, Maria (VerfasserIn) , Nordlind, Klas (VerfasserIn) , Sarafidis, Alexandre (VerfasserIn) , Vancheri, Carlo (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: March 18, 2014
In: Advances in therapy
Year: 2014, Jahrgang: 31, Heft: 4, Pages: 375-391
ISSN:1865-8652
DOI:10.1007/s12325-014-0112-1
Online-Zugang:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1007/s12325-014-0112-1
Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007%2Fs12325-014-0112-1
Volltext
Verfasserangaben:Ulrich Costabel, Elisabeth Bendstrup, Vincent Cottin, Pieter Dewint, Jim J. J. Egan, James Ferguson, Richard Groves, Per M. Hellström, Michael Kreuter, Toby M. Maher, Maria Molina-Molina, Klas Nordlind, Alexandre Sarafidis, Carlo Vancheri
Beschreibung
Zusammenfassung:Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free survival. Although generally well tolerated, a minority of patients discontinue therapy due to gastrointestinal and skin-related adverse events (AEs). This review summarizes recommendations based on existing guidelines, research evidence, and consensus opinions of expert authors, with the aim of providing practicing physicians with the specific clinical information needed to educate the patient and better manage pirfenidone-related AEs with continued pirfenidone treatment. The main recommendations to help prevent and/or mitigate gastrointestinal and skin-related AEs include taking pirfenidone during (or after) a meal, avoiding sun exposure, wearing protective clothing, and applying a broad-spectrum sunscreen with high ultraviolet (UV) A and UVB protection. These measures can help optimize AE management, which is key to maintaining patients on an optimal treatment dose.
Beschreibung:Gesehen am 25.08.2020
Beschreibung:Online Resource
ISSN:1865-8652
DOI:10.1007/s12325-014-0112-1

Ähnliche Einträge